Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study

PurposeOur study aims to examine the impact of definitive local therapy in prostate cancer patients with different metastatic sites.MethodsTotally, 5,849 patients diagnosed with metastatic prostate carcinoma from 2010 to 2014 were selected from Surveillance, Epidemiology, and End Results (SEER). Log-rank analyses, multivariable regression analysis, and Kaplan–Meier methods were used to assess prognostic impact of local treatment in patients with different metastatic sites. Survival curves and forest plots were also plotted to describe the prognostic value of definitive local therapy.ResultsIn our study, 159 patients received radical prostatectomy, and 62 received brachytherapy, while 5,628 did not receive local definitive local therapy. Survival analysis revealed that patients who received definitive local therapy had a better 5-year overall survival (OS) (P = 0.011) and cancer-specific survival (CSS) (P = 0.012). Multivariate regression analyses demonstrated that type of treatment was an independent prognostic indicator for OS (P = 0.011) and CSS (P = 0.012), along with age at diagnosis, chemotherapy, PSA level, and Gleason score. According to subgroup analysis, patients with bone metastasis or distant lymph node (LN) metastasis were significantly more likely to benefit from definitive local therapy. In addition, forest plots demonstrated that RP group had significant favorable OS and CSS in subgroups of younger age at diagnosis, T2–3 stage, N0–1 stage, Gleason score =7 or ≥8, bone metastasis, and distant LN metastasis.ConclusionsOur study suggested that local therapy improved survival in prostate cancer patients with bone or distant LN metastasis. Furthermore, patients who were at T2–3 stage or Gleason score ≥7 also significantly benefit from definitive local therapy.

Download Full-text

Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: Influence of Gleason score, treatment and bone metastasis

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2012.12.004 ◽

2013 ◽

Vol 67 (3) ◽

pp. 203-208 ◽

Cited By ~ 10

Author(s):

Vanessa Battisti ◽

Liési D.K. Maders ◽

Margarete D. Bagatini ◽

Iara E. Battisti ◽

Luziane P. Bellé ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Adenosine Deaminase ◽

Cancer Patients ◽

Gleason Score

Download Full-text

Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2011.06.003 ◽

2011 ◽

Vol 65 (7) ◽

pp. 516-524 ◽

Cited By ~ 29

Author(s):

Vanessa Battisti ◽

Liési D.K. Maders ◽

Margarete D. Bagatini ◽

Luiz Gustavo B. Reetz ◽

Juarez Chiesa ◽

...

Keyword(s):

Oxidative Stress ◽

Prostate Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Gleason Score ◽

Antioxidant Status

Download Full-text

Variation in local treatment of prostate cancer by hospital within New Jersey

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.14551 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 14551-14551

Author(s):

T. R. Blom ◽

R. A. Somer ◽

W. Shih ◽

M. Sarno ◽

D. McNally ◽

...

Keyword(s):

Prostate Cancer ◽

Multivariate Analysis ◽

Radiation Therapy ◽

New Jersey ◽

Gleason Score ◽

Local Treatment ◽

Local Therapy ◽

Geographic Region ◽

Diagnosis And Treatment ◽

Multivariate Logistic Regression Model

14551 Background: Although prostate cancer diagnosis and treatment vary through the US, few studies have assessed variations in local therapy between multiple hospitals located within a very narrow geographic region. Methods: To determine the variation of diagnosis and treatment of prostate cancer between hospitals in a local region, data was derived and analyzed from 1,301 patients from fifteen Cancer Institute of New Jersey Oncology Group network hospitals. Tumor registry data from patients with a histological confirmed diagnosis of prostate cancer accessioned over a one-year period between January 1, 2003 and December 31, 2003 was analyzed by a multivariate logistic regression model. Results: Median age of the cohort was 66 and mean number of cases diagnosed at these hospitals for this period was 87 (26–161). When the cohort was assessed overall, 192 cases assessed were African American, 1049 Caucasian, 51 Hispanic, and 32 Asian. Median Gleason score was 6. A total of 463 patients underwent Prostatectomy, and 538 had radiation therapy. Multivariate analysis demonstrated that age and hospital were associated with use of surgery versus no surgery. Race and Gleason score were not associated with use of surgery in this group of hospitals. Multivariate analysis also demonstrated that age and hospital were associated with utilizing radiation therapy versus not utilizing radiation therapy. Again, race and Gleason score were not associated with utilization of radiation therapy in these NJ hospitals. Conclusions: Overall, the most important factors predicting for surgery, and radiation therapy, were age and hospital, which were independent of race and Gleason score. These data support our ongoing assessment of hospital and geographic characteristics that may be responsible for these associations. No significant financial relationships to disclose.

Download Full-text

634P Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +/- docetaxel

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1147 ◽

2021 ◽

Vol 32 ◽

pp. S666

Author(s):

A. Carrot ◽

R-T. Elaidi ◽

O. Colomban ◽

D. Maillet ◽

M. Tod ◽

...

Keyword(s):

Prostate Cancer ◽

Kinetic Parameter ◽

Cancer Patients ◽

Prognostic Value ◽

Local Therapy ◽

Phase Iii ◽

Phase Iii Trial ◽

Prospective Phase

Download Full-text

Prognostic Value of the Serum Levels of Bone Formation and Bone Resorption Markers in Prostate Cancer Patients with Bone Metastasis

European Urology ◽

10.1159/000019700 ◽

1998 ◽

Vol 34 (2) ◽

pp. 142-147 ◽

Cited By ~ 7

Author(s):

Susumu Akimoto ◽

Hideji Inomiya ◽

Yuzo Furuya ◽

Koichiro Akakura ◽

Haruo Ito

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Bone Resorption ◽

Bone Formation ◽

Cancer Patients ◽

Prognostic Value ◽

Serum Levels ◽

Bone Resorption Markers

Download Full-text

Clinicopathological predictors of bone metastases in prostate cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e17520 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e17520-e17520

Author(s):

Ingreed Portilla ◽

Joseph Pinto ◽

Claudio J. Flores ◽

Jhajaira M Araujo ◽

Johanna A Villalobos ◽

...

Keyword(s):

Prostate Cancer ◽

Retrospective Study ◽

Bone Metastasis ◽

Bone Metastases ◽

Cancer Patients ◽

Gleason Score ◽

Clinical Stage ◽

Cross Sectional ◽

Pathological Characteristics ◽

Clinical Stages

e17520 Background: To determine if there is association between the clinical-pathological characteristics and the development of bone metastases in patients with prostate cancer treated in Oncosalud during the period 2016-2018. Methods: An observational, analytical, cross-sectional and retrospective study was conducted in 386 men diagnosed with prostate cancer in a Private Clinic in Peru. We presented descriptive and analytic analysis to identify variables associated with bone metastases; in addition, odds ratios were estimated. Results: In reference to the PSA groups, those patients with PSA values higher than 20 ng / ml presented a risk 9.69 times higher to develop bone metastases (95% CI: 5.08-18.45). In regard to Gleason groups, those with a 9-10 score presented a risk of bone metastasis 2.67 times higher than patients with lower Gleason score (95% CI: 1.31-5.45). In regard to the clinical stage, those patients with a T3 stage had a 6.77 higher risk than those with lower clinical stages (95% CI: 3.79-12.09). Conclusions: Clinical-pathological characteristics associated with bone metastasis were identified in patients with prostate cancer, including age, Gleason scale, PSA value and clinical T stage.

Download Full-text

Lesion-Based Bone Metastasis Detection in Chest Bone Scintigraphy Images of Prostate Cancer Patients Using Pre-Train, Negative Mining, and Deep Learning

Diagnostics ◽

10.3390/diagnostics11030518 ◽

2021 ◽

Vol 11 (3) ◽

pp. 518

Author(s):

Da-Chuan Cheng ◽

Te-Chun Hsieh ◽

Kuo-Yang Yen ◽

Chia-Hung Kao

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Deep Learning ◽

Bone Metastasis ◽

Cancer Patients ◽

Bone Scintigraphy ◽

Breast Cancer Patients ◽

Location Detection ◽

The Mean ◽

Mean Sensitivity

This study aimed to explore efficient ways to diagnose bone metastasis early using bone scintigraphy images through negative mining, pre-training, the convolutional neural network, and deep learning. We studied 205 prostate cancer patients and 371 breast cancer patients and used bone scintigraphy data from breast cancer patients to pre-train a YOLO v4 with a false-positive reduction strategy. With the pre-trained model, transferred learning was applied to prostate cancer patients to build a model to detect and identify metastasis locations using bone scintigraphy. Ten-fold cross validation was conducted. The mean sensitivity and precision rates for bone metastasis location detection and classification (lesion-based) in the chests of prostate patients were 0.72 ± 0.04 and 0.90 ± 0.04, respectively. The mean sensitivity and specificity rates for bone metastasis classification (patient-based) in the chests of prostate patients were 0.94 ± 0.09 and 0.92 ± 0.09, respectively. The developed system has the potential to provide pre-diagnostic reports to aid in physicians’ final decisions.

Download Full-text

Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.02.9439 ◽

2006 ◽

Vol 24 (13) ◽

pp. 1982-1989 ◽

Cited By ~ 58

Author(s):

Norihiko Tsuchiya ◽

Lizhong Wang ◽

Hiroyoshi Suzuki ◽

Takehiko Segawa ◽

Hisami Fukuda ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Genetic Polymorphisms ◽

Metastatic Prostate Cancer ◽

Genetic Factors ◽

Response To Treatment ◽

Logrank Test ◽

Ca Repeat ◽

Igf I

Purpose The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. Patients and Methods One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. Results Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). Conclusion The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.

Download Full-text